Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study

Friederike Holze, Matthias E. Liechti, Nadia R.P.W. Hutten, Natasha L. Mason, Patrick C. Dolder, Eef L. Theunissen, Urs Duthaler, Amanda Feilding, Johannes G. Ramaekers, Kim P.C. Kuypers

Abstract

There is a popular interest in microdosing with psychedelics such as LSD. This practice of using one-tenth of a full psychedelic dose according to a specific dosing schedule, anecdotally enhances mood and performance. Nonetheless, controlled research on the efficacy of microdosing is scarce. The main objective of the present dose-finding study was to determine the minimal dose of LSD needed to affect mood and cognition. A placebo-controlled within-subject study including 24 healthy participants, was conducted to assess the acute effects of three LSD doses (5, 10, and 20 mcg) on measures of cognition, mood, and subjective experience, up until 6 h after administration. Cognition and subjective experience were assessed using the Psychomotor Vigilance Task, Digit Symbol Substitution Test, Cognitive Control Task, Profile of Mood States, and 5-Dimensional Altered States of Consciousness rating scale. LSD showed positive effects in the majority of observations by increasing positive mood (20 mcg), friendliness (5, 20 mcg), arousal (5 mcg), and decreasing attentional lapses (5, 20 mcg). Negative effects manifested as an increase in confusion (20 mcg) and anxiety (5, 20 mcg). Psychedelic-induced changes in waking consciousness were also present (10, 20 mcg). Overall, the present study demonstrated selective, beneficial effects of low doses of LSD on mood and cognition in the majority of observations. The minimal LSD dose at which subjective and performance effects are notable is 5 mcg and the most apparent effects were visible after 20 mcg.

See more publications from the Beckley/Maastricht Psychedelic Programme

Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study

Brain, Behavior, and Immunity, 2023

Read more

Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study

European Journal of Pain

Read more

Spontaneous and deliberate creative cognition during and after psilocybin exposure

Translational Psychiatry, 2021

Read more

Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study

European Neuropsychopharmacology, 2020

Read more

Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants

Clinical Pharmacology and Therapeutics, 2020

Read more

Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers

ACS Pharmacology & Translational Science, 2020

Read more

A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers

Journal of Psychopharmacology, 2020

Read more

Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin

Nature – Neuropsychopharmacology, 2020

Read more